-
1
-
-
0025871150
-
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
-
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
-
(1991)
J Biol Chem
, vol.266
, pp. 12866-12872
-
-
Kujubu, D.A.1
Fletcher, B.S.2
Varnum, B.C.3
Lim, R.W.4
Herschman, H.R.5
-
2
-
-
0025754779
-
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
-
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
-
(1991)
Proc Natl Acad Sci USA
, vol.88
, pp. 2692-2696
-
-
Xie, W.L.1
Chipman, J.G.2
Robertson, D.L.3
Erikson, R.L.4
Simmons, D.L.5
-
3
-
-
0030461132
-
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
-
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-8.
-
(1996)
Nature
, vol.384
, pp. 644-648
-
-
Kurumbail, R.G.1
Stevens, A.M.2
Gierse, J.K.3
McDonald, J.J.4
Stegeman, R.A.5
Pak, J.Y.6
-
4
-
-
0029911267
-
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
-
Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 1996;3:927-33.
-
(1996)
Nature Struct Biol
, vol.3
, pp. 927-933
-
-
Luong, C.1
Miller, A.2
Barnett, J.3
Chow, J.4
Ramesha, C.5
Browner, M.F.6
-
5
-
-
0026588059
-
Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences
-
Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293:391-400.
-
(1992)
Arch Biochem Biophys
, vol.293
, pp. 391-400
-
-
Kraemer, S.A.1
Meade, E.A.2
DeWitt, D.L.3
-
6
-
-
0028147767
-
Structure of the human cyclo-oxygenase-2 gene
-
Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994;302:723-7.
-
(1994)
Biochem J
, vol.302
, pp. 723-727
-
-
Appleby, S.B.1
Ristimaki, A.2
Neilson, K.3
Narko, K.4
Hla, T.5
-
7
-
-
0030597962
-
Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
-
Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165-9.
-
(1996)
FEBS Lett
, vol.390
, pp. 165-169
-
-
Beiche, F.1
Scheuerer, S.2
Brune, K.3
Geisslinger, G.4
Goppelt-Struebe, M.5
-
8
-
-
0028034970
-
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
-
Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1995;94:2504-10.
-
(1995)
J Clin Invest
, vol.94
, pp. 2504-2510
-
-
Harris, R.C.1
McKanna, J.A.2
Akai, Y.3
Jacobson, H.R.4
Dubois, R.N.5
Breyer, M.D.6
-
9
-
-
13144260638
-
Pharmacological analysis of cyclooxygenase-1 in inflammation
-
Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95:13313-8.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 13313-13318
-
-
Smith, C.J.1
Zhang, Y.2
Koboldt, C.M.3
Muhammad, J.4
Zweifel, B.S.5
Shaffer, A.6
-
10
-
-
0036156424
-
Cyclooxygenase-2-10 years later
-
Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002;300:367-75.
-
(2002)
J Pharmacol Exp Ther
, vol.300
, pp. 367-375
-
-
Hinz, B.1
Brune, K.2
-
11
-
-
0031456454
-
Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
-
Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997;48:623-31.
-
(1997)
J Physiol Pharmacol
, vol.48
, pp. 623-631
-
-
Patrignani, P.1
Panara, M.R.2
Sciulli, M.G.3
Santini, G.4
Renda, G.5
Patrono, C.6
-
13
-
-
0034093534
-
Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
-
Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
-
(2000)
Drugs
, vol.59
, pp. 957-980
-
-
Clemett, D.1
Goa, K.L.2
-
15
-
-
0035833502
-
The coxibs, selective inhibitors of cyclooxygenase 2
-
Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase 2. N Engl J Med 2001;345:433-42.
-
(2001)
N Engl J Med
, vol.345
, pp. 433-442
-
-
Fitzgerald, G.A.1
Patrono, C.2
-
16
-
-
0034955602
-
An update on specific COX-2 inhibitors: The COXIBs
-
Gupta S, Crofford LJ. An update on specific COX-2 inhibitors: the COXIBs. Bull Rheum Dis 2001;50:1-4.
-
(2001)
Bull Rheum Dis
, vol.50
, pp. 1-4
-
-
Gupta, S.1
Crofford, L.J.2
-
19
-
-
0041664973
-
Rofecoxib: An update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects
-
Ahuja N, Singh A, Sing B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003;55:859-94.
-
(2003)
J Pharm Pharmacol
, vol.55
, pp. 859-894
-
-
Ahuja, N.1
Singh, A.2
Sing, B.3
-
21
-
-
0037329781
-
Clinical pharmacology of etoricoxib: A novel selective COX-2 inhibitor
-
Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin Phamacother 2003;4:265-74.
-
(2003)
Expert Opin Phamacother
, vol.4
, pp. 265-274
-
-
Patrignani, P.1
Capone, M.L.2
Tacconelli, S.3
-
22
-
-
0036707619
-
Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human
-
Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A, Findlay JW. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos 2002;30:1013-21.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 1013-1021
-
-
Yuan, J.J.1
Yang, D.C.2
Zhang, J.Y.3
Bible Jr., R.4
Karim, A.5
Findlay, J.W.6
-
23
-
-
0012762428
-
The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2
-
abstract SAT 0013
-
Marshall PJ, Berry C, Wasvary J, Van Duzer J, Du Z, Scott G, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 (abstract SAT 0013). Ann Rheum Dis 2002;61. (Suppl):S259.
-
(2002)
Ann Rheum Dis
, vol.61
, Issue.SUPPL.
-
-
Marshall, P.J.1
Berry, C.2
Wasvary, J.3
Van Duzer, J.4
Du, Z.5
Scott, G.6
-
24
-
-
0033665248
-
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
-
Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-32.
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 124-132
-
-
Leese, P.T.1
Hubbard, R.C.2
Karim, A.3
Isakson, P.C.4
Yu, S.S.5
Geis, G.S.6
-
25
-
-
0017279930
-
Mechanism of action of anti-inflammatory drugs
-
Brune K, Glatt M, Graf P. Mechanism of action of anti-inflammatory drugs. Gen Pharmacol 1976;7:27-33.
-
(1976)
Gen Pharmacol
, vol.7
, pp. 27-33
-
-
Brune, K.1
Glatt, M.2
Graf, P.3
-
26
-
-
0001525577
-
-
Eds: Bonta IL, Bray MA, Parnham MJ, Elsevier, Amsterdam
-
Brune K, Lanz R. Pharmacokinetics of non-steroidal anti-inflammatory drugs. The pharmacology of inflammation. Eds: Bonta IL, Bray MA, Parnham MJ, Elsevier, Amsterdam 1985. p. 413-49.
-
(1985)
Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs. The Pharmacology of Inflammation
, pp. 413-449
-
-
Brune, K.1
Lanz, R.2
-
27
-
-
0036163827
-
Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry
-
Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002;16:56-60.
-
(2002)
Biomed Chromatogr
, vol.16
, pp. 56-60
-
-
Werner, U.1
Werner, D.2
Pahl, A.3
Mundkowski, R.4
Gillich, M.5
Brune, K.6
-
28
-
-
0042126736
-
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
-
Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-7.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 130-137
-
-
Werner, U.1
Werner, D.2
Rau, T.3
Fromm, M.F.4
Hinz, B.5
Brune, K.6
-
29
-
-
0034805254
-
Rofecoxib versus codeine/acetaminophen in post-operative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial
-
Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP. Rofecoxib versus codeine/acetaminophen in post-operative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001;23:1446-55.
-
(2001)
Clin Ther
, vol.23
, pp. 1446-1455
-
-
Chang, D.J.1
Fricke, J.R.2
Bird, S.R.3
Bohidar, N.R.4
Dobbins, T.W.5
Geba, G.P.6
-
30
-
-
0036584829
-
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery
-
Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002;133:611-21.
-
(2002)
J Am Dent Assoc
, vol.133
, pp. 611-621
-
-
Daniels, S.E.1
Desjardins, P.J.2
Talwalker, S.3
Recker, D.P.4
Verburg, K.M.5
-
31
-
-
0035000968
-
Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor
-
Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001;29:813-20.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 813-820
-
-
Kassahun, K.1
McIntosh, I.S.2
Shou, M.3
Walsh, D.J.4
Rodeheffer, C.5
Slaughter, D.E.6
-
32
-
-
0035949182
-
Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans
-
Werner U, Werner D, Mundkowski R, Gillich M, Brune K. Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. J Chromatogr B Biomed Sci Appl 2001;760:83-90.
-
(2001)
J Chromatogr B Biomed Sci Appl
, vol.760
, pp. 83-90
-
-
Werner, U.1
Werner, D.2
Mundkowski, R.3
Gillich, M.4
Brune, K.5
-
33
-
-
0141771315
-
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects
-
abstract 281
-
Mangold JB, Gu H, Rodriguez LC, Scott G, Bonner J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects (abstract 281). Drug Metab Rev 2002;34. (Supp):S141.
-
(2002)
Drug Metab Rev
, vol.34
, Issue.SUPPL.
-
-
Mangold, J.B.1
Gu, H.2
Rodriguez, L.C.3
Scott, G.4
Bonner, J.5
Rordorf, C.6
-
34
-
-
2042457058
-
Lumiracoxib demonstrates high absolute bioavailability in healthy subjects
-
abstract P-199. Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag
-
Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects (abstract P-199). In: Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics.; 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag; 2003.
-
(2003)
Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics
-
-
Hartmann, S.1
Scott, G.2
Rordorf, C.3
Campestrini, J.4
Branson, J.5
Keller, U.6
-
35
-
-
1542330813
-
Lumiracoxib does not alter the pharmacokinetic profile or efficacy of the triphasic oral contraceptive Triphasil-28
-
abstract P-198. Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag
-
Kalbag J, Rordorf C, Wang Y, Caldwell J, Leese P, Scott G. Lumiracoxib does not alter the pharmacokinetic profile or efficacy of the triphasic oral contraceptive Triphasil-28 (abstract P-198). In: Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics.; 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag; 2003.
-
(2003)
Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics
-
-
Kalbag, J.1
Rordorf, C.2
Wang, Y.3
Caldwell, J.4
Leese, P.5
Scott, G.6
-
36
-
-
0034707105
-
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
-
VIGOR Study Group
-
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
-
(2000)
N Engl J Med
, vol.343
, pp. 1520-1528
-
-
Bombardier, C.1
Laine, L.2
Reicin, A.3
Shapiro, D.4
Burgos-Vargas, R.5
Davis, B.6
-
37
-
-
0034644396
-
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
-
Celecoxib Long-term Arthritis Safety Study
-
Silverstein FE, Faich G. Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. [Celecoxib Long-term Arthritis Safety Study.] J Am Med Assoc 2000;284:1247-55.
-
(2000)
J Am Med Assoc
, vol.284
, pp. 1247-1255
-
-
Silverstein, F.E.1
Faich, G.2
Goldstein, J.L.3
Simon, L.S.4
Pincus, T.5
Whelton, A.6
-
38
-
-
0034811819
-
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
-
Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2- specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001;23:1422-8.
-
(2001)
Clin Ther
, vol.23
, pp. 1422-1428
-
-
Harris, S.I.1
Kuss, M.2
Hubbard, R.C.3
Goldstein, J.L.4
-
39
-
-
0036794967
-
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis
-
Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.
-
(2002)
Eur J Gastroenterol Hepatol
, vol.14
, pp. 1101-1111
-
-
Sikes, D.H.1
Agrawal, N.M.2
Zhao, W.W.3
Kent, J.D.4
Recker, D.P.5
Verburg, K.M.6
-
40
-
-
0141852139
-
Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: A pilot endoscopic study in healthy male subjects
-
Rordorf C, Kellett N, Mair S, Ford M, Milosavljev S, Branson J, Scott G. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003;18:533-41.
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 533-541
-
-
Rordorf, C.1
Kellett, N.2
Mair, S.3
Ford, M.4
Milosavljev, S.5
Branson, J.6
Scott, G.7
-
41
-
-
0033050264
-
Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation
-
Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999;126:1200-4.
-
(1999)
Br J Pharmacol
, vol.126
, pp. 1200-1204
-
-
Wallace, J.L.1
Chapman, K.2
McKnight, W.3
-
42
-
-
0036967076
-
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation
-
Pinheiro RM, Calixto JB. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 2002;51:603-10.
-
(2002)
Inflamm Res
, vol.51
, pp. 603-610
-
-
Pinheiro, R.M.1
Calixto, J.B.2
-
43
-
-
0036100771
-
Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis
-
Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002;41:458-61.
-
(2002)
Rheumatology
, vol.41
, pp. 458-461
-
-
Knijff-Dutmer, E.A.1
Kalsbeek-Batenburg, E.M.2
Koerts, J.3
Van De Laar, M.A.4
-
44
-
-
0037322970
-
Strategies in pain management: New and potential indications for COX-2 specific inhibitors
-
Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003;25(Suppl):S21-31.
-
(2003)
J Pain Symptom Manage
, vol.25
, Issue.SUPPL.
-
-
Ruoff, G.1
Lema, M.2
-
45
-
-
0035924765
-
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
-
Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ. DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
-
(2001)
N Engl J Med
, vol.345
, pp. 1809-1817
-
-
Catella-Lawson, F.1
Reilly, M.P.2
Kapoor, S.C.3
Cucchiara, A.J.4
DeMarco, S.5
Tournier, B.6
-
46
-
-
0036219338
-
The mechanism of action of the new antiinflammatory compound ML3000: Inhibition of 5-LOX and COX-1/2
-
Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002;51:135-43.
-
(2002)
Inflamm Res
, vol.51
, pp. 135-143
-
-
Tries, S.1
Neupert, W.2
Laufer, S.3
|